Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis

  1. 1. Fostamatinib (Rheumatoid Arthritis) Forecast and MarketAnalysisReport Details:Published:November 2012No. of Pages: 47Price: Single User License – US$6995Fostamatinib (Rheumatoid Arthritis) Forecast and Market AnalysisSummaryGlobalData has released its new PharmaPoint Drug Evaluation report, Fostamatinib (RheumatoidArthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with theNovember 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaitingapproval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’sSYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt todislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven oncethey enter the market. Fostamatinib is an oral, small molecule that disrupts B-cell receptor-mediated signaling by inhibiting SYK. Its action affects the inflammatory mechanisms of TNF-a, IL-1, and IL-6. An in-license deal in 2010 has allowed the joint venture between RigelPharmaceuticals and AstraZeneca to bring this drug to Phase III development for oncology andRA. Regulatory filings are anticipated for 2013Scope- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatmentguidelines as well as an overview on the competitive landscape.- Detailed information on Fostamatinib including product description, safety and efficacy profiles aswell as a SWOT analysis.- Sales forecast for Fostamatinib for the top eight countries from 2011 to 2022.- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan andAustraliaReasons to buy- Understand and capitalize by identifying products that are most likely to ensure a robust return
  2. 2. - Stay ahead of the competition by understanding the changing competitive landscape forrheumatoid arthritis.- Effectively plan your M&A and partnership strategies by identifying drugs with the most promisingsales potential- Make more informed business decisions from insightful and in-depth analysis of Fostamatinibperformance- Obtain sales forecast for Fostamatinib from 2011 to 2022 in (the US, France, Germany, the UK,Italy, Spain, Japan and Australia)Get your copy of this report @ points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 41.1 List of Tables 61.2 List of Figures 62 Introduction 72.1 Catalyst 72.2 Related Reports 83 Disease Overview 103.1 Etiology and Pathophysiology 103.1.1 Etiology 103.1.2 Pathophysiology 103.1.3 Prognosis 133.1.4 Quality of Life 133.2 Symptoms 144 Disease Management 154.1 Overview 154.2 Diagnosis 154.3 Treatment 175 Competitive Assessment 215.1 Overview 215.2 Strategic Competitor Assessment 216 Opportunity and Unmet Need 236.1 Overview 236.2 Unmet Needs 246.2.1 More rheumatologists in the field and physician knowledge of the disease 246.2.2 More cost-effective therapies through oral formulation and biosimilars 246.2.3 The development of predictive tests and discovery of biomarkers 256.2.4 The discovery of curative therapies 256.2.5 Improved drug safety and efficacy profiles 25
  3. 3. 6.3 Gap Analysis 266.4 Opportunities 276.4.1 Predictive tools for diagnosis and treatment 276.4.2 Target specificity 277 Pipeline Assessment 287.1 Overview 287.2 Promising Drugs in Clinical Development 298 Fostamatinib (previously R788) 318.1 Overview 318.2 Efficacy 328.3 Safety 338.4 Dosing and Formulation 338.5 Potential Clinical Positioning 338.6 Potential Commercial Positioning 338.7 Pricing and Reimbursement 348.8 SWOT Analysis 348.9 Forecast 359 Appendix 369.1 Abbreviations 369.2 Bibliography 389.3 Methodology 429.4 Forecasting Methodology 429.4.1 Diagnosed Rheumatoid Arthritis Patients 429.4.2 Percent Drug-treated Patients 439.4.3 General Pricing Assumptions 439.4.4 Pricing of Pipeline agents 449.5 Physicians and Specialists Included in this Study 449.6 Primary Research - Prescriber Survey 459.7 About the Authors 459.7.1 Analysts 459.7.2 Global Head of Healthcare 469.8 About GlobalData 479.9 Contact Us 479.10 Disclaimer 471.1 List of TablesTable 1: Symptoms of Rheumatoid Arthritis 14Table 2: Treatment Guidelines for Rheumatoid Arthritis 18Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 20Table 4: Treatment Guidelines for Rheumatoid Arthritis 22Table 5: Overall Unmet Needs - Current Level of Attainment 23Table 6: Clinical Unmet Needs - Gap Analysis, 2012 27
  4. 4. Table 7: Rheumatoid Arthritis - Phase Pipeline, 2012 29Table 8: Comparison of Therapeutic Classes in Development for RA, 2012 30Table 9: Product Profile - Fostamatinib 31Table 10: ACR Responses and DAS28 Scores for Fostamatinib vs. Placebo at Month Three 32Table 11: Fostamatinib SWOT Analysis, 2012 34Table 12: Global Sales Forecasts ($m) for Fostamatinib 35Table 13: Physicians Surveyed, By Country 451.2 List of FiguresFigure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 10Figure 2: Rheumatoid Arthritis Biologic Drug Targets 12Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria PointSystem 16Figure 4: Severity of Rheumatoid Arthritis 17Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations*19Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 29Contact: for more information.